|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.02.26 - 13:36
|
Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders (Business Wire)
|
|
|
Lead program, SLTE-1009, licensed from DartsBio Pharmaceuticals (Guangdong), Ltd, is a potentially best-in-class anti-PACAP monoclonal antibody with half-life extension to enable subcutaneous dosing and is on track to initiate Phase 1 clinical trials in mid-2026
Financing was co-led by RA Capital Management, Forbion, and Foresite Capital with participation from an additional undisclosed biotech investor
PACAP (pituitary adenylate cyclase-activating polypeptide) is an emerging, clinically validated target for the prevention of migraines and potentially other headache disordersRALEIGH, N.C.--(BUSINESS WIRE)--Slate Medicines, Inc., a privately-held biotech company advancing next-generation therapeutics for headache disorders, today announced the close of a $130 million Series A financing, alongside the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody licensed from DartsBio Pharmaceuticals (Guangdong), Ltd.
Slate Medicines is led by Chief Executive Officer and Board Director Gregory Oakes, a bioph...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.10.25 - 12:03
|
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market (GlobeNewswire EN)
|
|
|
CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
